Biochemical and Imaging Diagnostics of Traumatic Brain Injury (BID-TBI) is a translational research project focusing on assessment of traumatic brain injuries (TBI) with novel multimodal approaches. TBI is a major public health problem globally: more than 50 million people have a TBI each year, and about half the world’s population will have one or more TBIs over their lifetime.
The BID-TBI project aims at accurate characterisation of individual TBI, identification of patients at increased risk of progressive brain damage, and therapeutic stratification to facilitate an individualised approach to management, as well as more accurate outcome prediction, and identification of molecular targets for future drug development. The project aims at results that can be easily adopted to the clinical practice.
The BID-TBI comprises four work packages including proteomics, metabolomics, lipidomics and imaging studies, which will be initiated and completed during the years 2019-2022.